China Antibody Drug Conjugates Market Size & Outlook
China antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
China antibody drug conjugates market highlights
- The China antibody drug conjugates market generated a revenue of USD 51.0 million in 2021 and is expected to reach USD 863.8 million by 2030.
- The China market is expected to grow at a CAGR of 36.9% from 2022 to 2030.
- In terms of segment, breast cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 51.0 million |
| Market revenue in 2030 | USD 863.8 million |
| Growth rate | 36.9% (CAGR from 2021 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Blood Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer, Other Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, China accounted for 0.9% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 863.8 million by 2030.
Breast cancer was the largest segment with a revenue share of 42.94% in 2021. Horizon Databook has segmented the China antibody drug conjugates market based on blood cancer, breast cancer, other cancer covering the revenue growth of each sub-segment from 2018 to 2030.
China’s ADC market is expected to grow at a significant rate over the forecast period, owing to increase in availability and focus on development of ADC therapies. Chinese companies such as Reme Gen Co., Ltd., Bio-Thera Solutions, and 3SBio Group are making significant investments in ADC drug development. Reme Gen Co., Ltd.’s lead ADC drug candidate, disitamab vedotin (RC48), was the first to undergo human studies in China.
The company has already filed for NDA of this product with the NMPA for treatment of stomach cancer. The drug was granted priority review in August 2020. In 2018, Bio-Thera Solutions’ lead ADC candidate, BAT8001, entered phase 3 trial for treatment of advanced HER2-positive breast cancer.
It skipped phase 2 clinical trials and surpassed RC48 by becoming the first ADC to have entered Phase 3 studies in China. The development and subsequent approval for ADC drugs by local players is expected to be one of the major factors driving the ADC market in China.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China antibody drug conjugates market size, by application, 2018-2030 (US$M)
China Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
